Metabolism News and Research

Latest Metabolism News and Research

Study provides evidence for safety and efficacy of chloroquine in COVID-19

After a pilot study (Huang et al.Journal of Molecular Cell Biology, in press), having proved the safety and effectiveness of the drug to reduce the viral RNA to undetectable levels in 10 COVID-19 patients, the researchers began this current study, published on the preprint server medRxiv.

5 May 2020

Sartorius launches the new Incucyte SX5® for live-cell analysis, offering new possibilities for live-cell analysis experiments

Sartorius, a leading international supplier for the biopharmaceutical industry, today launched the new Incucyte SX5 Live-Cell Analysis System, the latest in the company’s line of live-cell analysis products.

From Sartorius 5 May 2020

Different types of white fat may play distinct roles in metabolic diseases

Excess white fat causes obesity, which in turn can drive diabetes and many other metabolic diseases that are growing at epidemic rates around the world.

5 May 2020

Researchers discover new gene involved in regulating the body's cholesterol

Precision medicine has the potential to tailor treatments to a patient's unique genetic sequence. But achieving this precision -- or developing new drugs -- requires knowing which genes are involved in disease.

4 May 2020

Viruses from stool can help fight obesity and type 2 diabetes

Obese mice with unhealthy lifestyles gain significantly less weight and avoid type 2 diabetes when they receive viruses transplanted from the stool of lean mice. These are the findings of a new University of Copenhagen study.

4 May 2020

Study: Unique glucose-sensing neurons in the brain prevent severe hypoglycemia

Low blood sugar levels, known as hypoglycemia, can be a life-threatening situation, especially for people with type 1 diabetes who rely on intensive insulin therapy to prevent blood sugar from going too high.

4 May 2020

Blood sugar control is key for people with type 2 diabetes and COVID-19

A study reported in the journal Cell Metabolism on April 30 adds to the evidence that people with type 2 diabetes (T2D) are at greater risk of a poor outcome should they become infected with the virus that causes COVID-19.

4 May 2020

Remdesivir shows powerful activity against SARS-CoV-2 in Vitro

Remdesivir is an antiviral first developed by Gilead in 2014 as a treatment for Ebola and Marburg viruses. However, scientists explored its possibilities as a broad-spectrum drug when it proved effective against SARS-CoV and MERS-CoV, coronaviruses which were responsible for earlier outbreaks.

30 Apr 2020

New book provides the latest updates on obesity research

Obesity, defined as excessive fat accumulation that may impair health, has seen its prevalence increase to unprecedented levels globally, being projected to continue to rise.

29 Apr 2020

Researchers discover cause for the lack of immune defense against tumors

One of the reasons why cancer develops is because regulatory cells inhibit the body's immune defense. Researchers under the helm of the Technical University of Munich have discovered a mechanism for identifying regulatory cells in tumor tissue that suppress an immune response.

29 Apr 2020

Study explores the growth rate effect of gut bacteria on break down of dietary fibers

It is known that approximately 80% of human immune system functions in the gastrointestinal tract. Gut bacteria and their metabolites play a fundamental role in the interaction between gut and other organs.

29 Apr 2020

C-Path receives EMA’s letter of support to facilitate the diagnoses of type 1 diabetes

The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D) Consortium has received a letter of support from the European Medicines Agency (EMA) to facilitate the development and validation of the proposed regulatory qualification of pancreatic islet autoantibodies commonly used in clinical practice to diagnose T1D: insulin autoantibodies, glutamic acid decarboxylase 65, and insulinoma antigen-2 autoantibodies as enrichment biomarkers for T1D clinical trials.

29 Apr 2020

Schizophrenia related to abnormal fatty metabolism in the brain

Researchers discovered a brain deficiency in people with schizophrenia that could lead to development of new drug therapies.

28 Apr 2020

Antibiotic exposure and its priming effect on disease-causing bacteria

Antibiotics save lives -- but using them also helps antibiotic-resistant strains evolve and spread. Each year, antibiotic-resistant bacteria infect some 2.8 million people in the United States, killing more than 35,000, according to the Centers for Disease Control and Prevention.

27 Apr 2020

Prolonged corticosteroid treatment increases adrenal gland inflammation

New research by academics at the University of Bristol has found evidence that prolonged treatment of synthetic corticosteroid drugs increases adrenal gland inflammation in response to bacterial infection, an effect that in the long-term can damage adrenal function.

27 Apr 2020

Gut microbiota could predict severity of COVID-19

The COVID-19 pandemic is spreading to every corner of the world. But not everyone is falling sick at the same rate. A new study published on the preprint server medRxiv in April 2020 suggests that the composition of the gut microbiome could partially explain the difference in susceptibility. This adds a new dimension to what is currently known about the disease.

27 Apr 2020

Investigational drug may hold benefit for patients with lung and ovarian cancers

In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.

27 Apr 2020